X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27) 27
index medicus (25) 25
melanoma (23) 23
male (20) 20
female (19) 19
middle aged (19) 19
aged (18) 18
oncology (18) 18
cancer (17) 17
adult (15) 15
metastasis (14) 14
survival (14) 14
clinical trials (13) 13
melanoma - drug therapy (13) 13
care and treatment (11) 11
surgery (10) 10
aged, 80 and over (9) 9
melanoma - pathology (9) 9
research (9) 9
metastases (8) 8
analysis (7) 7
chemotherapy (7) 7
disease-free survival (7) 7
hematology, oncology and palliative medicine (7) 7
immunotherapy (7) 7
ipilimumab (7) 7
mutation (7) 7
skin neoplasms - pathology (7) 7
studies (7) 7
treatment outcome (7) 7
young adult (7) 7
antibodies, monoclonal - adverse effects (6) 6
cancer therapies (6) 6
dermatology (6) 6
italy (6) 6
melanoma - secondary (6) 6
patients (6) 6
risk factors (6) 6
survival rate (6) 6
adolescent (5) 5
double-blind method (5) 5
follow-up (5) 5
medical research (5) 5
melanoma - genetics (5) 5
melanoma - surgery (5) 5
metastatic melanoma (5) 5
prognosis (5) 5
safety (5) 5
survival analysis (5) 5
antibodies, monoclonal - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cobimetinib (4) 4
cutaneous melanoma (4) 4
development and progression (4) 4
esophageal cancer (4) 4
kinases (4) 4
lymphatic system (4) 4
medical prognosis (4) 4
medicine, research & experimental (4) 4
mek inhibition (4) 4
melanoma - mortality (4) 4
mortality (4) 4
mutations (4) 4
paper (4) 4
proto-oncogene proteins b-raf - genetics (4) 4
quality of life (4) 4
skin cancer (4) 4
skin neoplasms - drug therapy (4) 4
skin neoplasms - surgery (4) 4
vemurafenib (4) 4
abridged index medicus (3) 3
antibodies, monoclonal (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
complications and side effects (3) 3
dermoscopy (3) 3
diarrhea (3) 3
double-blind (3) 3
drug dosages (3) 3
drug therapy (3) 3
efficacy (3) 3
esophageal neoplasms - pathology (3) 3
esophageal neoplasms - surgery (3) 3
gene mutations (3) 3
immunology (3) 3
medicine (3) 3
medicine & public health (3) 3
medicine, experimental (3) 3
medicine, general & internal (3) 3
melanoma - diagnosis (3) 3
neoplasm staging (3) 3
patient outcomes (3) 3
pharmaceutical industry (3) 3
pharmacology (3) 3
radiation therapy (3) 3
scores (3) 3
skin neoplasms - diagnosis (3) 3
skin neoplasms - genetics (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 436 - 444
Summary Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-free survival... 
Hematology, Oncology and Palliative Medicine
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2018, Volume 19, Issue 5, pp. 603 - 615
Journal Article